Take Care Health Systems Offers Shingles Vaccine Nationwide
Take Care Health Systems, one of the largest managers of convenient care clinics and a wholly-owned subsidiary of Walgreens (NYSE, NASDAQ: WAG), is now administering the shingles vaccine at all 177 Take Care Health Clinics located at Walgreens drugstores in 19 markets throughout 14 states.
Successes In Global Immunisation Boost Progress Towards UN Millennium Development Goals
A revitalised global effort to improve immunisation programmes and strengthen health systems in the poorest countries is saving an increasing number of lives and making a significant impact towards achieving the UN Millennium Development Goals.
World's Top Vaccine Scientists To Discuss The Latest Research
Vaccines are critical tools in the fight to prevent high-burden infectious diseases in all age groups living in both industrialized and developing countries. Vaccine and public health experts will gather in Paris to review the promise of and challenges related to today's vaccine research, what new products are expected and to discuss the way forward.
Nventa Develops Proprietary Vaccine Adjuvant
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR), that has broad potential for use in both therapeutic and prophylactic vaccines. Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen.
A Single VSOP Can Do A 'Proton' Magic!
International research group led by Yasushi Okamura, a professor in Japanese National Institute for Physiological Sciences, Okazaki, and Peter Larsson, a professor in Oregon Health & Science University, Oregon, US, found that a single protein of VSOP, Voltage Sensor Only Protein/ Hv1, can carry protons even without making a multimeric complex.
Identification Of Immune Molecule That Plays A Powerful Role In Avoiding Organ Rejection
When a mouse's immune system is deciding whether to reject a skin graft, one powerful member of a molecular family designed to provoke such a response can effectively reduce the visibility of the mouse's own cells and help the graft survive, researchers say.
Discovery Rewrites Current Scientific Understanding Of How The Body Responds To Viruses
La Jolla Institute for Allergy & Immunology (LIAI) scientists have discovered one for the textbooks. Their finding, reported in the scientific journal Immunity, illuminates a new, previously unknown mechanism in how the body fights a virus. The finding runs counter to traditional scientific understanding of this process and will provide scientists a more effective method for developing vaccines.
Clue To How Dysentery Parasite Might Evade Immune System Discovered By Johns Hopkins Researchers
Every year, about 500 million people worldwide are infected with the parasite that causes dysentery, a global medical burden that among infectious diseases is second only to malaria. In a new study appearing in the June 15 issue of Genes and Development, Johns Hopkins researchers may have found a way to ease this burden by discovering a new enzyme that may help the dysentery-causing amoeba evade the immune system.
Romiplostim Data Show Potential Long-Term Efficacy And Safety In Adults With Chronic ITP
Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood.
Novartis Vaccines And Diagnostics S.r.l. Withdraws Its Marketing Authorisation Application For The Pre-pandemic Vaccine Aflunov, Europe
The European Medicines Agency (EMEA) has been formally notified by Novartis Vaccines and Diagnostics S.r.l. of its decision to withdraw the application for a centralised marketing authorisation for the pre-pandemic vaccine Aflunov (A/VietNam/1194/2004 (H5N1) virus surface inactivated antigen).